The prescription use of stimulants such as Ritalin and Adderall (methylphenidate and amphetamine, respectively) for the treatment of ADHD has been increasing. In 2007, the FDA mandated changes to drug labels for stimulants, based on findings about increased risk for psychosis. We studied whether the risk of psychosis in patients with ADHD differs among various stimulant types and found that patients prescribed amphetamine were at a higher risk of new psychosis requiring treatment with antipsychotic medicines than patients who had been prescribed methylphenidate.
Lauren Moran, M.D.
Harvard Medical School / McLean Hospital
2013 Young Investigator Grant
Jeffrey Borenstein, M.D.
President & CEO, Brain & Behavior Research Foundation
Host, Healthy Minds Television
Each month, BBRF hosts a complimentary Meet the Scientist Webinar. Join us online and learn about the latest research from international experts in the field of brain and behavior research. Complete webinar schedule >